PBAC's latest decision on Glofitamab: Recommended with restriction (2025). Considered for Treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after one or more lines of systemic therapy in patients ineligible for autologous stem cell transplant (ASCT).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Adult patients with relapsed or refractory DLBCL after one or more lines of systemic therapy, unsuitable for stem cell transplant, with WHO performance status of 2 or less.
Therapy area
Haematology
Line of therapy
Second-line
Evidence base
RCT
Primary endpoint
OS
Key trials
STARGLO, NP30179
Comparator
rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx)
Economic model
CEA
ICER note
ICER value not stated in the public summary document text provided.